Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Gastroenterol ; 58(11): 1081-1093, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37698719

RESUMO

Comprehensive genomic profiling based on next-generation sequencing has recently been used to provide precision medicine for various advanced cancers. Endoscopic ultrasound (EUS)-guided fine-needle aspiration (EUS-FNA) and EUS-guided fine-needle biopsy (EUS-FNB) play essential roles in the diagnosis of abdominal masses, mainly pancreatic cancers. In recent years, CGP analysis using EUS-FNA/FNB specimens for hepatobiliary-pancreatic cancers has increased; however, the success rate of CGP analysis is not clinically satisfactory, and many issues need to be resolved to improve the success rate of CGP analysis. In this article, we review the transition from EUS-FNA to FNB, compare each test, and discuss the current status and issues in genomic analysis of hepatobiliary-pancreatic cancers using EUS-FNA/FNB specimens.

2.
Intern Med ; 61(10): 1503-1509, 2022 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-34744108

RESUMO

Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has been shown to be useful in treating either advanced or recurrent KRAS/NRAS/BRAF wild-type colorectal cancer. We herein report the case of a 60-year-old man with short bowel syndrome who developed hematochezia due to panitumumab-induced colitis with vitamin K deficiency during third-line chemotherapy. The cause of vitamin K deficiency was the lack of intravenous vitamin K supplementation following a change from central venous nutrition to peripheral venous nutrition. We advise clinicians to carefully check for colitis and manage the infusions of chemotherapy patients with short bowel syndrome.


Assuntos
Antineoplásicos , Colite , Neoplasias Colorretais , Síndrome do Intestino Curto , Deficiência de Vitamina K , Anticorpos Monoclonais/efeitos adversos , Antineoplásicos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Colite/tratamento farmacológico , Neoplasias Colorretais/tratamento farmacológico , Hemorragia Gastrointestinal/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Mutação , Recidiva Local de Neoplasia/tratamento farmacológico , Panitumumabe/efeitos adversos , Proteínas Proto-Oncogênicas p21(ras)/metabolismo , Síndrome do Intestino Curto/tratamento farmacológico , Deficiência de Vitamina K/induzido quimicamente , Deficiência de Vitamina K/tratamento farmacológico
3.
Int Urol Nephrol ; 46(7): 1309-12, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24510251

RESUMO

Sunitinib, a molecular-targeted therapy, is a potential new treatment strategy for malignant pheochromocytoma. However, because of the rarity of malignant pheochromocytoma and the consequent limited number of patients available for clinical study, there is no good evidence of the efficacy of sunitinib for malignant pheochromocytoma. The present report describes our experience with sunitinib for refractory malignant pheochromocytoma. Two patients were treated with sunitinib at a standard dose (50 mg daily; 4 weeks on, 2 weeks off) after cyclophosphamide/vinblastine/dacarbazine chemotherapy, because vascular endothelial growth factor (VEGF)-positive cells were partly observed by immunohistochemical staining. Both patients were assessed as having stable disease according to the Response Evaluation Criteria in Solid Tumors 1.1. The duration of overall survival from the time sunitinib was initiated was 13 and 8 months, respectively, and the progression-free survival was 5 and 4 months, respectively. Adverse events were evaluated according to the Common Terminology Criteria for adverse events of the US Department of Health and Human Services version 4.0. One patient experienced hypothyroidism (Grade 2) and thrombocytopenia (Grade 2). The other patient experienced anorexia (Grade 3) and general malaise (Grade 3). In conclusion, sunitinib was effective in the treatment of malignant pheochromocytoma when VEGF-positive cells were observed in the tumor specimens.


Assuntos
Neoplasias das Glândulas Suprarrenais/cirurgia , Antineoplásicos/uso terapêutico , Indóis/uso terapêutico , Feocromocitoma/cirurgia , Pirróis/uso terapêutico , Neoplasias das Glândulas Suprarrenais/diagnóstico por imagem , Neoplasias das Glândulas Suprarrenais/mortalidade , Neoplasias das Glândulas Suprarrenais/patologia , Humanos , Imuno-Histoquímica , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade , Feocromocitoma/diagnóstico por imagem , Feocromocitoma/mortalidade , Feocromocitoma/patologia , Sunitinibe , Tomografia Computadorizada por Raios X , Fator A de Crescimento do Endotélio Vascular/metabolismo , Adulto Jovem
4.
J Endourol ; 27(2): 208-13, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23039311

RESUMO

BACKGROUND AND PURPOSE: Because of the limited working space available during retroperitoneal laparoscopic radical nephrectomy (LRN), the body habitus of the patient is likely to affect the risk of operative difficulties. This study sought to determine whether anthropometric measurements based on CT and abdominal radiography could be used to predict operative difficulties during retroperitoneal LRN. PATIENTS AND METHODS: Between August 2004 and January 2012, 96 consecutive patients with preoperative CT and abdominal radiography examinations underwent retroperitoneal LRN for a T(1) or T(2) stage renal tumor at our institution. The association between anthropometric measurements and demographics of patients and operative duration, estimated blood loss (EBL), and perioperative complications were retrospectively analyzed. Multivariate analysis was performed, and P<0.05 was considered significant. RESULTS: Anterior perirenal fat distance (P=0.016) and distance from the 12th rib to the iliac crest (P=0.038) were independently associated with operative duration. Only anterior perirenal fat distance (P=0.001) was independently associated with EBL. No intraoperative complications and reoperations occurred. The occurrence or severity of postoperative complications was not significantly associated with anthropometric measurements. Body mass index ≥25.0 kg/m(2) was not significantly associated with operative difficulties. CONCLUSION: The anterior perirenal fat distance and the distance from the 12th rib to the iliac crest can be used to predict operative difficulties during retroperitoneal LRN.


Assuntos
Antropometria , Laparoscopia , Nefrectomia/métodos , Espaço Retroperitoneal/cirurgia , Perda Sanguínea Cirúrgica , Humanos , Rim/diagnóstico por imagem , Rim/cirurgia , Laparoscopia/efeitos adversos , Análise Multivariada , Nefrectomia/efeitos adversos , Duração da Cirurgia , Radiografia Abdominal , Espaço Retroperitoneal/diagnóstico por imagem , Tomografia Computadorizada por Raios X
5.
Int Urol Nephrol ; 44(6): 1611-6, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22893496

RESUMO

OBJECTIVES: Periprostatic local anesthesia for transrectal ultrasound (TRUS)-guided prostate biopsy requires additional needle punctures and injection of local anesthetics into the periprostatic area. This study sought to determine the influence of periprostatic local anesthesia on the surgical difficulty of open radical prostatectomy (RP). PATIENTS AND METHODS: A total of 241 consecutive patients who underwent TRUS-guided prostate needle biopsy were randomized to receive either periprostatic nerve block (Anesthesia group; n=120) or no anesthesia (Control group; n=121). After diagnosing localized prostate cancer, patients who underwent open RP without neoadjuvant androgen deprivation therapy were evaluated as to whether perioperative nerve block affected operative duration, estimated blood loss (EBL), positive margin rate or complications. RESULTS: Twenty-one patients in the Anesthesia group and 19 patients in the Control group were investigated in the current study. In assessing the patients who underwent open RP with or without periprostatic nerve block, no significant differences in operative duration, EBL, positive margin rate or complications were seen between groups. CONCLUSION: Periprostatic nerve block does not appear to affect perioperative outcomes after open RP.


Assuntos
Anestesia Local , Biópsia por Agulha , Próstata/patologia , Prostatectomia , Neoplasias da Próstata/patologia , Neoplasias da Próstata/cirurgia , Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino , Pessoa de Meia-Idade , Bloqueio Nervoso , Estudos Prospectivos , Prostatectomia/efeitos adversos
6.
Int J Urol ; 18(11): 785-91, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21902723

RESUMO

OBJECTIVES: To investigate the effects of long-term administration of the α(1) -adrenoceptor antagonist prazosin on afferent inputs from the lower urinary tract (LUT). METHODS: Twenty female spontaneously hypertensive rats (SHR) were randomized to receive a 4-week course of prazosin (0.12 mg/kg per day) or vehicle; 10 female Wistar-Kyoto (WKY) rats were given vehicle. Prazosin or vehicle was administered via an osmotic pump. The effect of prazosin on urodynamic parameters was determined by continuous cystometry in conscious animals. After cystometry, rats were killed and c-fos expression in the dorsal horn of the L6 spinal cord was measured by immunohistochemistry. RESULTS: The bladder contraction interval was significantly shorter in untreated SHR compared with WKY rats (2.36 ± 0 vs 4.27 ± 0.12 min, respectively; P < 0.05) and cystometric capacity was decreased significantly in SHR compared with WKY rats. L6 spinal cord c-Fos expression was also significantly greater in SHR than WKY rats. The administration of prazosin significantly increased the micturition interval (4.07 ± 0.58 min; P < 0.05) and bladder capacity, but it did not affect micturition pressure. In SHR, the number of c-Fos-positive neurons was significantly lower following the administration of prazosin compared with vehicle. CONCLUSIONS: Increased afferent input from the LUT may induce an increase in urinary frequency in SHR. Furthermore, long-term administration of prazosin can exert inhibitory effects on afferent pathways from the LUT during the storage phase. Reductions of afferent input can result in increased bladder capacity and increased micturition interval.


Assuntos
Antagonistas de Receptores Adrenérgicos alfa 1/farmacologia , Prazosina/farmacologia , Medula Espinal/química , Bexiga Urinária/fisiologia , Urodinâmica/efeitos dos fármacos , Animais , Feminino , Imuno-Histoquímica , Vértebras Lombares , Neurônios Aferentes/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-fos/análise , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKY , Medula Espinal/patologia , Fatores de Tempo , Micção/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA